TriSalus Life Sciences, Inc. Common Stock (TLSI) Stock
Key stats
- Market cap
- $141.91M
- Price / Earnings ratio
- -3.0x
- EPS (TTM)
- -$1.21
- Volume
- Loading
- 52-week high
- $7.95
- 52-week low
- $2.20
Source: third-party data provider, as of November 13, 2026
Compare with TLSI
Recent news

TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TLSI

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
TLSI

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TLSI

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TLSI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 22.48
- MACD 12/26/9
- -0.34
- EMA 9 of MACD
- -0.25
- MACD histogram
- -0.09
- SMA 50
- $4.15
- Price below SMA 50
- EMA 50
- $3.96
- Price below EMA 50
- SMA 200
- $4.31
- Price below SMA 200
- EMA 200
- $4.53
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TLSI

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
TLSI

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TLSI

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TLSI

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TLSI

TriSalus Life Sciences Q2 Earnings Call Highlights
TriSalus Life Sciences Q2 Earnings Call Highlights
TLSI

TriSalus Life Sciences Reports Second Quarter 2026 Results
TriSalus Life Sciences Reports Second Quarter 2026 Results
TLSI

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TLSI

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
TLSI

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TLSI
News tone: automated (AI) classification of the article's content, not a price prediction.
About TriSalus Life Sciences, Inc. Common Stock
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Mary T. Szela B.S.N., M.B.A. | CEO, President & Director | 1964 |
| Mr. David B. Patience | Chief Financial Officer | 1986 |
| Dr. Richard B. Marshak M.B.A., VMD | Chief Commercial Officer | 1959 |
| Andrea Marasso | Vice President of Marketing | — |
| Ms. Jennifer L. Stevens J.D. | Chief Regulatory, Quality and Therapeutics Officer | 1962 |
| Dr. Bryan F. Cox Ph.D. | Chief of Research | 1962 |
| Dr. Richard Marshall M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 22.48
- MACD 12/26/9
- -0.34
- EMA 9 of MACD
- -0.25
- MACD histogram
- -0.09
- SMA 50
- $4.15
- Price below SMA 50
- EMA 50
- $3.96
- Price below EMA 50
- SMA 200
- $4.31
- Price below SMA 200
- EMA 200
- $4.53
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $7.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.2 | +24.0 | +1.8 | +4.2 | -16.6 | -10.8 | -21.5 |



